Danlianxin Formula Ameliorates Cardiac Dysfunction Associated with Myocardial Infarction in Hyperlipidemic Rats via Epac1/VDAC1/NLRP3/Caspase Signaling Pathway
ObjectiveTo investigate the improvement effect and mechanism of Danlianxin formula (DLXF) on cardiac function associated with myocardial infarction (MI) in hyperlipidemic rats.MethodsThe hyperlipidemia model was established by feeding rats a high-fat diet for 8 weeks, followed by the MI modeling induced by ligating the left anterior descending coronary artery. After 4 weeks of gavage administration of DLXF at low (1.108 g·kg-1·d-1) and high (2.217 g·kg-1·d-1) doses, the following assessments were conducted: Observation of physical signs, echocardiography for cardiac function, histopathological examination for cardiac morphology, laser speckle contrast imaging for mesenteric microvascular perfusion, serum biochemical tests for key lipid parameters such as total cholesterol (TC) and triglycerides (TG), as well as inflammatory cytokines including interleukin-1












